138 related articles for article (PubMed ID: 3317753)
1. Tumor necrosis factor and interleukin 1 as mediators of endotoxin-induced beneficial effects.
Urbaschek R; Urbaschek B
Rev Infect Dis; 1987; 9 Suppl 5():S607-15. PubMed ID: 3317753
[TBL] [Abstract][Full Text] [Related]
2. Interdependence of the radioprotective effects of human recombinant interleukin 1 alpha, tumor necrosis factor alpha, granulocyte colony-stimulating factor, and murine recombinant granulocyte-macrophage colony-stimulating factor.
Neta R; Oppenheim JJ; Douches SD
J Immunol; 1988 Jan; 140(1):108-11. PubMed ID: 2447166
[TBL] [Abstract][Full Text] [Related]
3. Tumor necrosis factor induced stimulation of granulopoiesis and radioprotection.
Urbaschek R; Männel DN; Urbaschek B
Lymphokine Res; 1987; 6(3):179-86. PubMed ID: 3306175
[TBL] [Abstract][Full Text] [Related]
4. Temporal sequence of pulmonary cytokine gene expression in response to endotoxin in C3H/HeN endotoxin-sensitive and C3H/HeJ endotoxin-resistant mice.
Nill MR; Oberyszyn TM; Ross MS; Oberyszyn AS; Robertson FM
J Leukoc Biol; 1995 Nov; 58(5):563-74. PubMed ID: 7595058
[TBL] [Abstract][Full Text] [Related]
5. The therapeutic potential of interleukin-1 and tumor necrosis factor on hematopoietic stem cells.
Moreb J; Zucali JR
Leuk Lymphoma; 1992 Nov; 8(4-5):267-75. PubMed ID: 1290956
[TBL] [Abstract][Full Text] [Related]
6. Endotoxin, tumor necrosis factor-alpha and interleukin 1 induce interleukin 6 production in vivo.
Shalaby MR; Waage A; Aarden L; Espevik T
Clin Immunol Immunopathol; 1989 Dec; 53(3):488-98. PubMed ID: 2805453
[TBL] [Abstract][Full Text] [Related]
7. Differential priming for endotoxin-induced circulating cytokine production by tumor necrosis factor-alpha and interleukin 1 beta.
Le Contel C; Vinit MA; Parant FJ; Parant MA
Cytokine; 1990 Sep; 2(5):375-80. PubMed ID: 2103335
[TBL] [Abstract][Full Text] [Related]
8. Recombinant interleukin-1 alpha and recombinant tumor necrosis factor alpha synergize in vivo to induce early endotoxin tolerance and associated hematopoietic changes.
Vogel SN; Kaufman EN; Tate MD; Neta R
Infect Immun; 1988 Oct; 56(10):2650-7. PubMed ID: 3262089
[TBL] [Abstract][Full Text] [Related]
9. Does endotoxin tolerance prevent the release of inflammatory monokines (interleukin 1, interleukin 6, or tumor necrosis factor) during sepsis?
Ayala A; Kisala JM; Felt JA; Perrin MM; Chaudry IH
Arch Surg; 1992 Feb; 127(2):191-6; discussion 196-7. PubMed ID: 1540097
[TBL] [Abstract][Full Text] [Related]
10. Prevention and treatment of endotoxin and sepsis lethality with recombinant human tumor necrosis factor.
Sheppard BC; Fraker DL; Norton JA
Surgery; 1989 Aug; 106(2):156-61; discussion 161-2. PubMed ID: 2669193
[TBL] [Abstract][Full Text] [Related]
11. Human recombinant interleukin-1 alpha protection against the lethality of endotoxin and experimental sepsis in mice.
Alexander HR; Doherty GM; Fraker DL; Block MI; Swedenborg JE; Norton JA
J Surg Res; 1991 May; 50(5):421-4. PubMed ID: 2038179
[TBL] [Abstract][Full Text] [Related]
12. Tumor necrosis factor: a cytokine involved in toxic effects of endotoxin.
Männel DN; Northoff H; Bauss F; Falk W
Rev Infect Dis; 1987; 9 Suppl 5():S602-6. PubMed ID: 3500495
[TBL] [Abstract][Full Text] [Related]
13. Corticosteroids alter hematopoiesis in vitro by enhancing human monocyte secretion of granulocyte colony-stimulating factor.
Rinehart J; Keville L; Clayton S; Figueroa JA
Exp Hematol; 1997 May; 25(5):405-12. PubMed ID: 9168062
[TBL] [Abstract][Full Text] [Related]
14. Treatment of BCL-1 murine B-cell leukemia with recombinant cytokines. Comparative analysis of the anti-leukemic potential of interleukin 1 beta (IL-1 beta), interleukin 2 (IL-2), interleukin-6 (IL-6), tumor necrosis factor alpha (TNF alpha), granulocyte colony stimulating factor (G-CSF), granulocyte-macrophage colony stimulating factor (GM-CSF), and their combination.
Chelstrom LM; Finnegan D; Uckun FM
Leuk Lymphoma; 1992 May; 7(1-2):79-86. PubMed ID: 1282065
[TBL] [Abstract][Full Text] [Related]
15. Radioprotection and therapy of radiation injury with cytokines.
Neta R
Prog Clin Biol Res; 1990; 352():471-8. PubMed ID: 2205873
[TBL] [Abstract][Full Text] [Related]
16. Endotoxin-induced cytokine gene expression in vivo. II. Regulation of tumor necrosis factor and interleukin-1 alpha/beta expression and suppression.
Ulich TR; Guo KZ; Irwin B; Remick DG; Davatelis GN
Am J Pathol; 1990 Nov; 137(5):1173-85. PubMed ID: 2240164
[TBL] [Abstract][Full Text] [Related]
17. The importance of a lipopolysaccharide-initiated, cytokine-mediated host defense mechanism in mice against extraintestinally invasive Escherichia coli.
Cross A; Asher L; Seguin M; Yuan L; Kelly N; Hammack C; Sadoff J; Gemski P
J Clin Invest; 1995 Aug; 96(2):676-86. PubMed ID: 7635960
[TBL] [Abstract][Full Text] [Related]
18. Macrophage endotoxin tolerance: effect of TNF or endotoxin pretreatment.
Li MH; Seatter SC; Manthei R; Bubrick M; West MA
J Surg Res; 1994 Jul; 57(1):85-92. PubMed ID: 8041155
[TBL] [Abstract][Full Text] [Related]
19. Downregulation of the proinflammatory cytokine response to endotoxin by pretreatment with the nontoxic lipid A analog SDZ MRL 953 in cancer patients.
Kiani A; Tschiersch A; Gaboriau E; Otto F; Seiz A; Knopf HP; Stütz P; Färber L; Haus U; Galanos C; Mertelsmann R; Engelhardt R
Blood; 1997 Aug; 90(4):1673-83. PubMed ID: 9269788
[TBL] [Abstract][Full Text] [Related]
20. Tumor necrosis factor mediates the effects of endotoxin on cholesterol and triglyceride metabolism in mice.
Memon RA; Grunfeld C; Moser AH; Feingold KR
Endocrinology; 1993 May; 132(5):2246-53. PubMed ID: 8477669
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
